424 related articles for article (PubMed ID: 11165114)
1. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.
Jenney AW; Lum G; Fisher DA; Currie BJ
Int J Antimicrob Agents; 2001 Feb; 17(2):109-13. PubMed ID: 11165114
[TBL] [Abstract][Full Text] [Related]
2. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia.
Crowe A; McMahon N; Currie BJ; Baird RW
Int J Antimicrob Agents; 2014 Aug; 44(2):160-2. PubMed ID: 24924662
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Burkholderia pseudomallei isolates in Northern Vietnam.
Nhung PH; Van VH; Anh NQ; Phuong DM
J Glob Antimicrob Resist; 2019 Sep; 18():34-36. PubMed ID: 30685463
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method.
Maloney S; Engler C; Norton R
J Glob Antimicrob Resist; 2017 Sep; 10():291-294. PubMed ID: 28729203
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against biofilm of Brazilian strains of Burkholderia pseudomallei.
Bandeira Tde J; Moreira CA; Brilhante RS; Castelo-Branco Dde S; Neto MP; Cordeiro Rde A; Rodrigues Tde J; Rocha MF; Sidrim JJ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5771-3. PubMed ID: 24002089
[TBL] [Abstract][Full Text] [Related]
6. Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials.
Karunakaran R; Puthucheary SD
Scand J Infect Dis; 2007; 39(10):858-61. PubMed ID: 17852912
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.
Bugrysheva JV; Sue D; Gee JE; Elrod MG; Hoffmaster AR; Randall LB; Chirakul S; Tuanyok A; Schweizer HP; Weigel LM
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396541
[No Abstract] [Full Text] [Related]
8. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.
Wuthiekanun V; Amornchai P; Saiprom N; Chantratita N; Chierakul W; Koh GC; Chaowagul W; Day NP; Limmathurotsakul D; Peacock SJ
Antimicrob Agents Chemother; 2011 Nov; 55(11):5388-91. PubMed ID: 21876049
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore.
Sivalingam SP; Sim SH; Aw LT; Ooi EE
J Antimicrob Chemother; 2006 Nov; 58(5):1102-3. PubMed ID: 16951412
[No Abstract] [Full Text] [Related]
10. Melioidosis: antibiogram of cases in Singapore 1987-2007.
Tan AL; Tan ML
Trans R Soc Trop Med Hyg; 2008 Dec; 102 Suppl 1():S101-2. PubMed ID: 19121668
[TBL] [Abstract][Full Text] [Related]
11. The antibiotics of choice for the treatment of melioidosis in Indian set up.
Shaw T; Tellapragada C; Eshwara VK; Bhat HV; Mukhopadhyay C
Indian J Med Microbiol; 2016; 34(3):353-4. PubMed ID: 27514960
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility and genetic characterisation of Burkholderia pseudomallei isolated from Malaysian patients.
Khosravi Y; Vellasamy KM; Mariappan V; Ng SL; Vadivelu J
ScientificWorldJournal; 2014; 2014():132971. PubMed ID: 25379514
[TBL] [Abstract][Full Text] [Related]
13. False-positive widal in melioidosis.
Valsalan R; Shubha S; Mukhopadhyay C; Saravu K; Maneesh M; Shastry BA; Rau NR; Pandit VR; Gonsalves H
Indian J Med Sci; 2009 Oct; 63(10):464-7. PubMed ID: 19901486
[TBL] [Abstract][Full Text] [Related]
14. Farnesol increases the susceptibility of Burkholderia pseudomallei biofilm to antimicrobials used to treat melioidosis.
Castelo-Branco DS; Riello GB; Vasconcelos DC; Guedes GM; Serpa R; Bandeira TJ; Monteiro AJ; Cordeiro RA; Rocha MF; Sidrim JJ; Brilhante RS
J Appl Microbiol; 2016 Mar; 120(3):600-6. PubMed ID: 26669506
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility patterns of Burkholderia pseudomallei among melioidosis cases in Kedah, Malaysia.
Hassan MR; Vijayalakshmi N; Pani SP; Peng NP; Mehenderkar R; Voralu K; Michael E
Southeast Asian J Trop Med Public Health; 2014 May; 45(3):680-8. PubMed ID: 24974653
[TBL] [Abstract][Full Text] [Related]
16. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.
Sam IC; See KH; Puthucheary SD
J Clin Microbiol; 2009 May; 47(5):1556-8. PubMed ID: 19297597
[TBL] [Abstract][Full Text] [Related]
17. Melioidosis acquired by traveler to Nigeria.
Salam AP; Khan N; Malnick H; Kenna DT; Dance DA; Klein JL
Emerg Infect Dis; 2011 Jul; 17(7):1296-8. PubMed ID: 21762592
[TBL] [Abstract][Full Text] [Related]
18. Management of melioidosis.
Wuthiekanun V; Peacock SJ
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):445-55. PubMed ID: 16771621
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.
Chetchotisakd P; Chierakul W; Chaowagul W; Anunnatsiri S; Phimda K; Mootsikapun P; Chaisuksant S; Pilaikul J; Thinkhamrop B; Phiphitaporn S; Susaengrat W; Toondee C; Wongrattanacheewin S; Wuthiekanun V; Chantratita N; Thaipadungpanit J; Day NP; Limmathurotsakul D; Peacock SJ
Lancet; 2014 Mar; 383(9919):807-14. PubMed ID: 24284287
[TBL] [Abstract][Full Text] [Related]
20. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.
Chierakul W; Anunnatsiri S; Short JM; Maharjan B; Mootsikapun P; Simpson AJ; Limmathurotsakul D; Cheng AC; Stepniewska K; Newton PN; Chaowagul W; White NJ; Peacock SJ; Day NP; Chetchotisakd P
Clin Infect Dis; 2005 Oct; 41(8):1105-13. PubMed ID: 16163628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
